Pancreatic cancer data kept dominating AACR conversations as Revolution Medicines reported updated clinical performance for daraxonrasib, including first-line results and continued signs of deep activity. The company’s AACR disclosures built on prior late-stage signals, reinforcing investor focus on RAS(ON) inhibition strategies designed to extend survival in a disease where options remain limited. At the same meeting, additional early-phase oncology signals emerged in both targeted therapy and ADC categories. QLS5132, a CLDN6-targeting ADC combining a monoclonal antibody with a topoisomerase I payload, showed preliminary clinical benefit in platinum-resistant ovarian cancer, with partial responses in a dose-escalation Phase I cohort and no treatment-related deaths. Separately, University of Pennsylvania researchers presented first-in-human Phase I data for SynKIR-110, a multi-chain KIR-CAR T design aiming to create an “on-off” activation pattern intended to reduce T-cell exhaustion risk in solid tumors. The early reports described a favorable safety profile and disease stabilization across multiple mesothelin-expressing cancer types.